PubMed Health⌕ Search

Biomedical subjects

L B Lazebnik

Publications and source records attributed to L B Lazebnik.

At least 37 records · Page 2Linked to original sources
PubMed2004

[Non-steroidal anti-inflammatory drugs and tramadol in the treatment of osteoarthrosis deformans in patients with arterial hypertension].

The prohypertensive effect of non-steroidal anti-inflammatory drugs (NSAIDs) can be manifested by the decreased efficiency of antihypertensive therapy. The tactics of their differential use in relation to the its effect on blood pressure (BP) in patients with osteoarthrosis (OA) and arterial hypertension (AH) has not been developed for the most effective and safe therapy. In this connection, it is extremely urgent to study the comparative safety of used NSAIDs as to their prohypertensive effect and to work out the management of patients with AH and OA. Ninety-eight patients with second-third degree OA of the knee and hip joints concurrent with the pain syndrome and first-second grade AH were followed up. Diclofenac, ketoprofen, arthrotec, nimesulide, and meloxicam were used. In a control group, the analgesic tramadol was supplemented to the therapy. AH was controlled by enalapril monotherapy. In groups of patients receiving diclofenac, arthrotec, meloxicam, and ketoprofen, there was a trend for the number of cases of an adequate nocturnal BP lowering (Dipper) to reduce and for those of an inadequate nocturnal BP decrease (Non-dipper), which may be accounted for by the prohypertensive effect of these drugs; this trend was most pronounced in the diclofenac and arthrotec groups. Despite its marked prohypertensive effect, nimesulide did not impair circadian BP variations. The central-acting analgesic tramadol exerted no prohypertensive effect and it did not increase BP values. The prohypertensive effect of the tested NSAIDs and tramadol increases in the following order: tramadol, ketoprofen, meloxicam, nimesulide, arthrotec, diclofenac.

Analgesics, Opioid↗
PubMed2004

[Celecoxib and Tramadol as an alternative osteoarthrosis therapy in patients with NSAID gastropathy].

OBJECTIVE: To determine whether it is possible to continue the anti-inflammatory NSAID therapy of osteoarthrosis patients with the NSAID-induced duodenal ulcer. The results of the treatment of 38 patients with osteoarthrosis of II-III degrees in which the NSAID treatment was complicated with duodenal ulcers were analyzed. The treatment of 20 osteoarthrosis patients was carried out with the help of Celecoxib while 18 patients were on Tramadol as an analgesic therapy against a standard antiulcer therapy. The efficacy of osteoarthrosis treatment was assessed based on the pain syndrome dynamics by the VAS and functional Lequin test; the efficacy of duodenal ulcer treatment was assessed on the basis of clinical signs dynamics under EGD (esophagogastroduodenoscopy). A clinical remission (the endoscopy confirmed the healing of the ulcerous affection) was achieved in 19 Celecoxib patients with duodenal ulcer and osteoarthrosis, and 18 Tramadol patients with osteoarthrosis and duodenal ulcer against a standard antiulcer therapy. Celecoxib can serve as a drug of choice for continuing the anti-inflammatory and analgesic therapy in patients with osteoarthrosis and NSAID gastropathy.

Analgesics, Opioid↗
PubMed2004

[Particular features of the concurrent course of arterial hypertension and ulcer in elderly patients].

The article presents a clinical course analysis in elderly patients suffering concurrently from arterial hypertension and ulcer as well as a study of the state of the mucous coat of the stomach and duodenum at the endoscopy and morphological assessment. It gives data of the daily monitoring of arterial pressure, central hemodynamics and indices of the lipid blood composition and hemorheology. There was a comparative analysis, which established the direct dependence of the ulcerous defect area on the atherogeneity index. Data of the morphological assessment seem to be most interesting as this study revealed abnormalities in microcirculation in the mucous coat of the stomach. It should be noted that disorders in the blood supply of the mucous coat of the stomach play a considerable role in the formation of ulcers in elderly patients with long-term arterial hypertension, and semination with Helicobacter pylori is very rare.

Aged↗
PubMed2003

[Clinicomorphological changes of liver in atherogenic dyslipidemia and after treatment with statins].

AIM: To evaluate clinicofunctional and morphological changes in the liver of patients with atherogenic dyslipidemia and in the course of treatment with statins. MATERIAL AND METHODS: A general clinical examination, biochemical hepatic tests, determination of blood lipid spectrum, markers of viral hepatites B, C, G, TT, ultrasound hepatic imaging of the liver of bile ducts, punch biopsy of the liver were made in 60 patients (38 females and 22 males) at the age of 39 to 70 years with atherogenic dyslipidemia (ADL). RESULTS: Biochemical tests showed high activity of transaminases (1.5-2 times higher than normal) in 16 patients, hyperbilirubinemia in 12 patients, dyslipidemia of type IIb-III in all the examinees. Ultrasound investigation of the liver has found fat dystrophy in 58, cholesterosis of the gallbladder in 32, cholelithiasis in 17 patients. Histological examination of the liver evidenced for marked fat dystrophy of hepatocytes, perihepatocellular and periportal fibrosis, moderate portal and periportal hepatitis. 22 of 54 patients treated with statins appeared to have morphological signs of drug damage to the liver. CONCLUSION: ADL patients' livers are characterized by signs of non-alcoholic steatohepatitis. In its presence stains treatment leads to development of drug-related hepatic disorder--statin hepatitis. Therefore, hypolipidemic drugs in non-alcoholic steatohepatitis must be used individually or alternative treatments should be tried.

Adult↗
PubMed2002

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

AIMS: To evaluate the safety and efficacy of levosimendan in patients with left ventricular failure complicating acute myocardial infarction. METHODS AND RESULTS: Levosimendan at different doses (0.1-0.4 microg x kg(-1) x min(-1)) or placebo were administered intravenously for 6h to 504 patients in a randomised, placebo-controlled, double-blind study. The primary end-point was hypotension or myocardial ischaemia of clinical significance adjudicated by an independent Safety Committee. Secondary end-points included risk of death and worsening heart failure, symptoms of heart failure and all-cause mortality. The incidence of ischaemia and/or hypotension was similar in all treatment groups (P=0.319). A higher frequency of ischaemia and/or hypotension was only seen in the highest levosimendan dose group. Levosimendan-treated patients experienced lower risk of death and worsening heart failure than patients receiving placebo, during both the 6h infusion (2.0% vs 5.9%; P=0.033) and over 24h (4.0% vs 8.8%; P=0.044). Mortality was lower with levosimendan compared with placebo at 14 days (11.7% vs 19.6%; hazard ratio 0.56 [95% CI 0.33-0.95];P =0.031) and the reduction was maintained at the 180-day retrospective follow-up (22.6% vs 31.4%; 0.67 [0.45-1.00],P =0.053). CONCLUSION: s Levosimendan at doses 0.1-0.2 microg x kg(-1) x min(-1) did not induce hypotension or ischaemia and reduced the risk of worsening heart failure and death in patients with left ventricular failure complicating acute myocardial infarction.

Acute Disease↗